NeOnc Technologies Executes Sub-License Agreement, Marking Key Milestone Toward Closing $50 Million Strategic Partnership with Quazar Investment

Core Insights - NeOnc Technologies Holdings, Inc. has achieved a significant milestone by executing a Sub-License Agreement with its Abu Dhabi subsidiary, NuroCure, covering the UAE and wider GCC and MENA region for its therapeutics NEO100 and NEO212 [1][2] - The company is progressing towards a strategic partnership with Quazar Investment, which includes a potential $50 million equity investment aimed at expanding operations in the MENA region [2][5] - NeOnc's inclusion in the Russell Microcap Index is strategically timed with the Quazar partnership to attract institutional capital and enhance market liquidity [3] Company Developments - The Sub-License Agreement is the second of five required conditions for closing the transaction with Quazar, indicating progress in the partnership [2][5] - The proposed capital formation round led by Quazar is priced at $25 per share, with 70% of proceeds allocated for acquiring NeOnc common stock and 30% for clinical trials and infrastructure development in the MENA region [5] - NeOnc's NEO100 and NEO212 therapeutics are currently in Phase II clinical trials and have received FDA Fast-Track and Investigational New Drug (IND) status, showcasing the company's commitment to advancing life-saving therapies [6] Strategic Goals - The completion of the Sub-License Agreement is viewed as a critical step in unlocking the full potential of the $50 million partnership, aimed at delivering long-term value to shareholders [4] - The company is undergoing a transformation from a clinical-stage biotech to a global brain cancer platform, as noted by industry experts [4] - NeOnc has an extensive patent portfolio licensed from the University of Southern California, which supports its drug development efforts and extends patent protections to 2038 [6]